Annual Update of Filing Fees

SUMMARY: In accordance with the Commission regulations, the Commission issues this update of its filing fees. This notice provides the yearly update using data in the Commission’s Financial System to calculate the new fees. The purpose of updating is to adjust the fees on the basis of the Commission’s costs for Fiscal Year 2017.

DATES: Effective Date: February 5, 2018.


SUPPLEMENTARY INFORMATION: Document Availability: In addition to publishing the full text of this document in the Federal Register, the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the internet through FERC’s Home Page (http://www.ferc.gov) and in FERC’s Public Reference Room during normal business hours (8:30 a.m. to 5:00 p.m., Eastern time) at 888 First Street NE, Room 2A, Washington, DC 20426.

From FERC’s website on the internet, this information is available in the eLibrary. The full text of this document is available on eLibrary in PDF and Microsoft Word format for viewing, printing, and/or downloading. To access this document in eLibrary, type the docket number excluding the last three digits of this document in the docket number field and follow other directions on the search page.

User assistance is available for eLibrary and other aspects of FERC’s website during normal business hours. For assistance, contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll free at (866) 208–3676, or for TTY, contact (202) 502–8659.

Annual Update of Filing Fees

Effective Date: February 5, 2018.

The Federal Energy Regulatory Commission (Commission) is issuing this notice to update filing fees that the Commission assesses for specific services and benefits provided to identifiable beneficiaries. Pursuant to 18 CFR 381.104, the Commission is establishing updated fees on the basis of the Commission’s Fiscal Year 2017 costs. The adjusted fees announced in this notice are effective February 5, 2018. The Commission has determined, with the concurrence of the Administrator of the Office of Information and Regulatory Affairs of the Office of Management and Budget, that this final rule is not a major rule within the meaning of section 251 of Subtitle E of Small Business Regulatory Enforcement Fairness Act, 5 U.S.C. 804(2). The Commission is submitting this final rule to both houses of the United States Congress and to the Comptroller General of the United States.

The new fee schedule is as follows:

Fees Applicable to the Natural Gas Policy Act

<table>
<thead>
<tr>
<th>Fee Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petitions for rate approval pursuant to 18 CFR 284.123(b)(2)</td>
<td>$13,500</td>
</tr>
</tbody>
</table>

Fees Applicable to General Activities

<table>
<thead>
<tr>
<th>Fee Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petition for issuance of a declaratory order (except under Part I of the Federal Power Act)</td>
<td>$27,130</td>
</tr>
<tr>
<td>Review of a Department of Energy remedial order: Amount in controversy</td>
<td>100</td>
</tr>
<tr>
<td>$0–9,999. (18 CFR 381.303(b))</td>
<td></td>
</tr>
<tr>
<td>$10,000–29,999. (18 CFR 381.303(b))</td>
<td>600</td>
</tr>
<tr>
<td>$30,000 or more. (18 CFR 381.303(a))</td>
<td>39,610</td>
</tr>
<tr>
<td>Review of a Department of Energy denial of adjustment: Amount in controversy</td>
<td>100</td>
</tr>
<tr>
<td>$0–9,999. (18 CFR 381.304(b))</td>
<td></td>
</tr>
<tr>
<td>$10,000–29,999. (18 CFR 381.304(b))</td>
<td>600</td>
</tr>
<tr>
<td>$30,000 or more. (18 CFR 381.304(a))</td>
<td>20,770</td>
</tr>
<tr>
<td>Written legal interpretations by the Office of General Counsel</td>
<td>7,780</td>
</tr>
</tbody>
</table>

Fees Applicable to Natural Gas Pipelines

<table>
<thead>
<tr>
<th>Fee Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pipeline certificate applications pursuant to 18 CFR 284.224</td>
<td>*1,000</td>
</tr>
</tbody>
</table>

Fees Applicable to Cogenerators and Small Power Producers

<table>
<thead>
<tr>
<th>Fee Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certification of qualifying status as a small power production facility</td>
<td>$23,330</td>
</tr>
<tr>
<td>Certification of qualifying status as a cogeneration facility</td>
<td>$26,410</td>
</tr>
</tbody>
</table>

* This fee has not been changed.
List of Subjects in 18 CFR Part 381

Electric power plants, Electric utilities, Natural gas, reporting and recordkeeping requirements.

Anton C. Porter,
Executive Director.

In consideration of the foregoing, the Commission amends Part 381, Chapter I, Title 18, Code of Federal Regulations, as set forth below.

PART 381—FEES

§ 381.302 [Amended]
1. In 381.302, paragraph (a) is amended by removing "$25,640" and adding "$27,130" in its place.

§ 381.303 [Amended]
2. In 381.303, paragraph (a) is amended by removing "$37,430" and adding "$39,610" in its place.

§ 381.304 [Amended]
3. In 381.304, paragraph (a) is amended by removing "$12,760" and adding "$13,500" in its place.

§ 381.505 [Amended]
4. In 381.505, paragraph (a) is amended by removing "$22,050" and adding "$23,330" in its place.

§ 381.403 [Amended]
5. Section 381.403 is amended by removing "$12,760" and adding "$13,500" in its place.

§ 381.505 [Amended]
6. In 381.505, paragraph (a) is amended by removing "$22,050" and adding "$23,330" in its place and by removing "$24,960" and adding "$26,410" in its place.

[FR Doc. 2017–28466 Filed 1–3–18; 8:45 am]
BILLING CODE 6717–01–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

21 CFR Part 1308
[Docket No. DEA–474]

Schedules of Controlled Substances: Temporary Placement of Cyclopropyl Fentanyl in Schedule I

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Temporary amendment; temporary scheduling order.

SUMMARY: The Administrator of the Drug Enforcement Administration is issuing this temporary scheduling order to schedule the synthetic opioid, N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (cyclopropyl fentanyl), and its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers in schedule I. This action is based on a finding by the Administrator that the placement of cyclopropyl fentanyl in schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. As a result of this order, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances will be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle, cyclopropyl fentanyl.

DATES: This temporary scheduling order is effective January 4, 2018, until January 4, 2020. If this order is extended or made permanent, the DEA will publish a document in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598–6812.

SUPPLEMENTARY INFORMATION:

Legal Authority

Section 201 of the Controlled Substances Act (CSA), 21 U.S.C. 811, provides the Attorney General with the authority to temporarily place a substance in schedule I of the CSA for two years without regard to the requirements of 21 U.S.C. 811(h) if he finds that such action is necessary to avoid an imminent hazard to the public safety. 21 U.S.C. 811(h)(1). In addition, if proceedings to control a substance are initiated under 21 U.S.C. 811(a)(1), the Attorney General may extend the temporary scheduling for up to one year, 21 U.S.C. 811(h)(2).

Where the necessary findings are made, a substance may be temporarily scheduled if it is not listed in any other schedule under section 202 of the CSA, 21 U.S.C. 812, or if there is no exemption or approval in effect for the substance under section 505 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. 355. 21 U.S.C. 811(h)(1). The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA. 28 CFR 0.100.

Background

Section 201(b)(4) of the CSA, 21 U.S.C. 811(b)(4), requires the Administrator to notify the Secretary of the Department of Health and Human Services (HHS) of his intention to temporarily place a substance in schedule I of the CSA. The Administrator transmitted notice of his intent to place cyclopropyl fentanyl in schedule I on a temporary basis to the Assistant Secretary for Health of HHS by letter dated August 28, 2017. The Assistant Secretary responded by letter dated September 6, 2017, and advised that based on review by the Food and Drug Administration (FDA), there are currently no investigational new drug applications or approved new drug applications for cyclopropyl fentanyl. The Assistant Secretary also stated that the HHS has no objection to the temporary placement of cyclopropyl fentanyl in schedule I of the CSA. The DEA has taken into consideration the Assistant Secretary’s comments as required by 21 U.S.C. 811(h)(4).

Cyclopropyl fentanyl is not currently listed in any schedule under the CSA, and no exemptions or approvals are in effect for cyclopropyl fentanyl under section 505 of the FDCA, 21 U.S.C. 355. The DEA has found that the control of cyclopropyl fentanyl in schedule I on a temporary basis is necessary to avoid an imminent hazard to the public safety, and as required by 21 U.S.C. 811(h)(1)(A), a notice of intent to temporarily schedule cyclopropyl fentanyl was published in the Federal Register on November 21, 2017. 82 FR 5533.

To find that placing a substance temporarily in schedule I of the CSA is necessary to avoid an imminent hazard to the public safety, the Administrator is required to consider three of the eight factors set forth in section 201(c) of the CSA, 21 U.S.C. 811(c): The substance’s

1 Though DEA has used the term “final order” with respect to temporary scheduling orders in the past, this document adheres to the statutory language of 21 U.S.C. 811(h), which refers to a “temporary scheduling order.” No substantive change is intended.

2 As discussed in a memorandum of understanding entered into by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS in carrying out the Secretary’s scheduling responsibilities under the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations. 58 FR 35460, July 1, 1993.